Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

Chris Fordham is Managing Partner of Ernst & Young's Fraud Investigation & Dispute Services unit for Asia Pacific. He has been in the accounting profession for 25 years, and has lived in Hong Kong for 17 years.

As a forensic accounting expert, Chris has extensive experience in forensic investigation, fraud, corruption (including the US Foreign Corrupt Practices Act) and anti- money laundering risk consulting, involving the review of company controls and systems for fraud risk and AML framework development and implementation.

He has worked on a large number of investigations related to sales manipulation, employee and procurement fraud, and financial misstatement issues. He is also deeply experienced in expert witness and general litigation support, involving the preparation of reports for use in both commercial and criminal disputes.

Chris is Chairman and a Founding Member of the Steering Group of the Forensic Interest Group established by the Hong Kong Institute of Certified Public Accountants (HKICPA). He is a Certified Member of the Association of Certified Fraud Examiners (CFE), a Qualified Dispute Resolver on the Academy of Experts' Register of Mediators (QDR), a Fellow of the Association of Chartered Certified Accountants (FCCA), a Member of the HKICPA, and a Member of the Insolvency Practitioners Association (MIPA).

Donemark Calimon is a partner and the head of Quisumbing Torres' Dispute Resolution Practice Group. In addition to specializing in domestic and international commercial arbitration, he has extensive experience in compliance-related advisory and litigation matters. He regularly advises pharmaceutical companies on matters relating to Philippine anti-bribery and corruption laws, consumer-related laws and other regulatory matters. He has helped clients develop or improve compliance-related processes and provide its employees training on these process, such as dawn raids.

Michael K. Loucks, a nationally recognized health care fraud prosecutor, joined the firm as a litigation partner in the Boston office in July 2010. With 25 years in public service, Mr. Loucks most recently was Acting U.S. Attorney and First Assistant U.S. Attorney for the District of Massachusetts, where he led major criminal and civil investigations, as well as many of the most high-profile health care fraud prosecutions of the past two decades.

Before serving as Acting U.S. Attorney, Mr. Loucks had a long history in the Massachusetts U.S. Attorney's Office. He was First Assistant U.S. Attorney (2005-2009); White Collar Crime Section Chief (2005); Health Care Fraud Unit Chief (1997-2004); and Health Care Fraud Coordinator (1992-2004).

Mr. Loucks speaks frequently at seminars and symposia on prosecutions, corporate compliance and litigation-related issues associated with the health care, pharmaceutical and medical devices sectors. He also writes extensively on these topics and is the co-author of Prosecuting and Defending Health Care Cases, the leading treatise in the area.

In 2011, Mr. Loucks received the Burton Award for Legal Achievement, which recognizes excellence in legal scholarship. He was selected in the Boston Business Journal's inaugural ?Who's Who in Legal Services? (March 11, 2011).

Joseph B. Tompkins, Jr. is a partner in the Washington, D.C. office of the international law firm, Sidley Austin LLP. He serves as a Global Coordinator of Sidley's Complex Commercial Litigation practice and as one of the leaders of the Firm's Foreign Corrupt Practices Act practice, which involves over 90 lawyers. Sidley's FCPA/Anti-Corruption investigations have involved activities in over 100 countries to date. Mr. Tompkins' experience includes service with the Criminal Division of the U.S. Department of Justice from 1979-1982, where he served as Deputy Chief of the Fraud Section from 1980-1982.

Emmanuel is the Leader of EY's Fraud Investigation & Dispute Services in Greater China.

He has 20 years of experience in forensic accounting, anti-bribery/anti-corruption reviews, transactions forensics and litigation support, including 18 years in Hong Kong and Shanghai.

In the pharmaceutical and medical devices sectors, Emmanuel has carried out numerous enquiries involving suspected improper payments to HCPs and KOLs through expense schemes, third party intermediaries or vendors. He is also routinely involved in risk and compliance assessments at the Chinese operations of MNCs as well as anti-bribery/anti-corruption due diligence projects.

Campbell Clark is General Counsel, Asia, for the Covidien Group and is based in Singapore. Covidien was acquired by Medtronic in January 2015, and he now engaged in integration activities in the Asia Pacific region for Medtronic. In his role with Covidien, Campbell continues to lead his team in Singapore in providing legal support to Covidien's medical devices business, training centers, R&D facilities, and manufacturing plants in the region. Prior to joining Covidien in 2008, Mr Clark was the Assistant General Counsel, Australia and New Zealand, for Tyco International. He has also held senior roles in house as an international legal counsel in Japan, and in private practice as a litigation lawyer in New Zealand and the United Kingdom.

Mr Clark graduated from the University of Auckland, New Zealand, and holds an LL.B (Hons) and M.Jur (Dist.).

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

Accountable for driving Abbott's Regional Ethics and Compliance Program in Asia region across its hugely diversified businesses i.e. Nutritional Products, Diabetes Care, Medical Optics, Vascular, Diagnostics, Pharmaceuticals and Molecular. One goal in mind: Nurture a robust organisation wide mindset of Triple Lenses of Responsibilities Framework -- Ethics, Economics/Finance and the Law.

An accomplished International Ethics & Compliance professional with combined 18 years of proven track record from scaling up to sustaining the Compliance Program together with Global and Regional key stakeholders. Experienced leading complex Audits and Investigations that resulted in a more robust internal controls structure and FCPA/ Anti-Bribery Anti-Corruption detective and preventive measures being put in place.

An outstanding people manager whose leadership philosophy is having a clear vision, empowering, coaching and the right intervention.

A Harvard Business School trained and well regarded industry thought leader. Rhys is currently the co-chairperson for Asia Pharmaceutical Compliance Congress, faculty member of Seton Hall University's Asia-Pacific Healthcare Compliance Program, founding member of the Asia-Pacific Healthcare Compliance Industry Group and member of the Harvard Business School Healthcare Alumni Association.

Georgie practises in commercial disputes, with a particular focus on regulatory disputes and investigations. She advises companies on a range of compliance and regulatory issues including anti-money laundering, anti-corruption, whistleblowing and regulator investigations. Georgie has advised on a range of local and international bribery issues.

Georgie joined Baker & McKenzie's Sydney office in March 2003, following seven years working for Norton Rose in London. During her time at Norton Rose she was seconded to the UK Listing Authority, investigating and enforcing breaches of the UK Listing Rules and assisting with the development of the market abuse regime. Georgie was also seconded to HSBC Investment Bank's Compliance team advising in relation to the Bank's information barriers.

Roderick Vega (Erick) is a Partner of SyCip Gorres Velayo & Co (SGV), the member firm of EY in the Philippines. Erick heads the Fraud Investigation and Dispute Services (FIDS) practice of SGV. As a FIDS Partner, he leads the Firm's FIDS works for investigations, IT forensics, forensic data analytics, compliance, disputes, fraud risk assessments and anti-fraud trainings. He has a combined working experience of more than 24 years, with the last 10 years devoted mainly to fraud investigation and dispute services.

Riza holds degrees in AB English and Bachelor of Laws. She started her legal career in 2000 specializing in commercial law, IP, tax and labor. She moved to Sanofi Philippines in 2006, becoming Legal, Public Affairs and Communications Director there, before joining Novartis in 2011.

Riza was an active member of the PHAP Committees on Public Affairs (2007-2011) and Integrity & Compliance (2012-2015).

Michael Woodward is the General Manager for The Red Flag Group's Asia-Pacific operations. Michael was formerly a lawyer in Australia, and prior to his appointment as General Manager, was in charge of all legal and compliance related matters for The Red Flag Group, and before that was a consultant in the Advisory team.

Michael has successfully developed and managed compliance programmes for various international clients, and was responsible for the implementation of The Red Flag Group's very own best-in-class compliance and risk management system. Having previously worked in private practice in Sydney, Australia, Michael has built specialist knowledge in anti-bribery and corruption, anti-trust and data privacy. Michael has led compliance related projects throughout the Asia-Pacific region and the Middle-East, and has supported major client initiatives in the US.

Michael has received extensive training in legal and compliance matters, and is a thoughtful and engaging facilitator of training seminars and workshops which he has provided for multi-national organisations in numerous jurisdictions.

Emmanuelle joined Novartis in 2001 as Legal Counsel to the Novartis Global Primary Care Business Unit in Basel, Switzerland. After having served in roles of increasing responsibility across Novartis Oncology and Novartis Vaccines & Diagnostics, Emmanuelle relocated to Singapore in 2013 to become the Head of legal & compliance for Sandoz APAC.

She is a Swiss national and received her Master of Law and Master of Health Economics and Management from the University of Lausanne as well as a Master of European & International Business Law from the University of St. Gallen, both in Switzerland. She is a Swiss qualified attorney.

Clarissa Shen is Country Compliance Head, responsible for designing an effective Compliance Program for Sanofi China to uphold Sanofi Group's highest ethical standards.

Clarissa has extensive business management experiences in the area of credit management, supply chain management; and distributorship and agent management with world's leading Pharmaceutical and Chemical companies. Since year 2009, Clarissa has progressed her career, having acted as acting compliance head for Bristol-Myers Squib (China) and associate compliance director for Eli Lilly Asia.
Clarissa graduated from Shanghai University with a bachelor degree and obtained an UK accredited MBA degree from University of Canterbury, Christchurch New Zealand.

Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

Marjotin "Marj" Javellana is MSD Philippines' Director for Business Excellence and Alliance Management. She leads a team of sales & marketing professionals responsible for managing MSD Philippines' Marketing & Sales Effectiveness, Business Practices & Ethics, Alliance, and Learning & Development.

Marj has been working in the pharmaceutical industry and with MSD for over 2 decades, starting her career in the industry as a Medical Representative and taking on roles of progressing responsibilities through the years. A Six Sigma greenbelt, Marj has extensive experience in sales management, salesforce effectiveness, business process standardization, leading and driving change initiatives, compliance & risk management, and design & implementation of training related to these.

Marj took a shift in her career in 2010 and moved to compliance as Country Compliance Officer for MSD Philippines. As Director for Compliance for the AP Sub-Region from 2012 to early 2015, she had varying responsibilities that included Philippines and the countries of Thailand, Malaysia, Singapore, Vietnam and Australia. Marj moved back to country operations to lead MSD Philippines' Business Excellence and Alliance Management in February 2015.

Paul Peterson is a Director in the Forensic, Investigative and Dispute Resolution Services practice in the Shanghai office for Grant Thornton. Paul focuses on fraud investigations, global anti-corruption, litigation support and consulting services around forensic accounting and anti-fraud programs and controls.

Paul has subject matter expertise in the area of the Foreign Corrupt Practices Act (?FCPA?) and global anti-corruption and has led investigations in many countries including Germany, Italy, UK, Switzerland, India and China.

From both an audit and investigatory perspective, Paul has worked with company management and executives, internal audit departments, internal and external counsel and audit committees.

Redentor R. Romero is the APAC Director of Compliance for Teva Pharmaceutical Investments Singapore Pte Ltd, where he is responsible for formulating and developing the Compliance Program for Teva in Asia Pacific. He is a lawyer by profession and was the Regional Legal Counsel for AstraZeneca for the Asia Area before joining Teva. Prior to joining the pharma industry, he was in legal practice, focusing on litigation, contracts and labor law.

Andy Bender is Polaris' founder. As a hands-on executive, Andy has been involved in a wide variety of compliance-related engagements for pharmaceutical and device manufacturers, ranging from policy development and process automation to organizational change. His expertise ranges from the sales and marketing to medical and clinical departments of the client organization. Andy is still involved in many of Polaris' client assignments, and has personally led many FMV, auditing and monitoring projects, as well as numerous international transparency reporting and HCP/O implementations.

Polaris has over 110 pharmaceutical and med device clients and employs a staff of more than 250, including five healthcare law attorneys. Polaris has offices in New York, Amsterdam, San Francisco, Paris and Boston.

Maria Eugenia (Maru) Quindimil is Senior Director APAC at GEC Risk Advisory LLC, the global governance, risk, integrity, reputation and crisis advisory firm (www.GECRisk.com) serving executives, boards, investors and advisors in diverse sectors, growth stages and industries, primarily in the Americas, Europe and Africa. Client assignments range from strategic to tactical, including enterprise and specific risk assessments, crisis planning, integrity program development, codes of conduct, and customized education from the boardroom to the shop floor.

Ms. Quindimil, the former Executive Director, Regional Compliance Officer, Asia for Merck Sharp & Dohme, Asia Ltd., led regional Compliance groups, comprising 26 professional staff in 20 Asia Pacific countries (10,000 employees) for 8 years. She successfully implemented the Foreign Corrupt Practices Acts (FCPA) in the region, the first Merck region to significantly reduce corrupt practice risk; used Six Sigma methodologies to simplify processes and develop an innovative scorecard and electronic platform to review compliance programs at the country level and ensure follow up monitoring; and improved key risk areas, including 90% reduction in samples management cases the first year. She co-created Asia Pacific Escalation, Investigation, Remediation and Recognition guidelines that were adopted by Merck globally. During the last two years, she created a strong process to handle Third Parties contracted in different capacities enhancing their compliance programs and governance processes.

In 2015 she was internationally recognized by the World Women Congress Leadership organization for her outstanding contributions in the region with the "Women Leadership Achievement Award." This award is given to outstanding women professionals who have demonstrated vision, flair, acumen and management skills in an organization making changes and achieving results sponsored by World Federation of Marketing professionals, Stars of the Industry Group, Asia Confederation of Business and World CSR Day.

Throughout a career that has spanned 25 years, Maru has applied her background in pharmaceutical and pharmacological research into the commercial pharmaceutical sector where she led the development, launch and market growth of several new products across a diverse range of geographic sectors. She has received several awards and recognition for achieving targets and significantly exceeding sales budgets. Her commercial background provides a broader strategic view of the role of compliance in operations, and has influenced management, regional leadership and boards of directors through innovative systems and processes. Her focus is to bring behavioral changes among leaders as well as rank-and-file.

Known for a flexible and situational leadership style, she is committed to enabling and optimizing the performance of teams from diverse backgrounds and across different work environments.

Maru has led APEC Pharmaceutical sector meetings for the implementation of Pharmaceutical codes of conduct, is a current Board member of Asia Pacific Compliance Group, and has been Chair and Speaker at Asia Pacific Pharmaceutical Compliance Congress for the last 4 years as well as a frequent speaker for IFPMA. A native Argentinian, Maru has lived and worked in Latin America, Europe, the USA and Asia Pacific region, and is fluent in English, Spanish and Portugese.

Maru has degrees in Biochemistry and Pharmacy from Universidad de Buenos Aires, Argentina; MBA from Instituto de Altos Estudios Empresariales from Universidad Austral, Argentina, Human Resources Master degree from Centro Estudios Financieros, Spain and graduated from Strategic Leadership Program from Institute of Leadership, Otago University, New Zealand.

Robert joined Transparency International UK in 2008 and was appointed as Executive Director in 2013. His areas of expertise include the Bribery Act, integrity in the private sector and corruption within the UK. Recent projects and publications include ?Anti-Bribery Due Diligence for Transactions', ?Adequate Procedures -- Guidance to the UK Bribery Act' and ?Corruption in the UK'. He was previously Director of Governance & Sustainable Investment at F&C Asset Management, and CEO (Europe) of the environmental research group Earthwatch Institute.

He was a member of the Ministry of Justice's Experts Group drafting the official guidance on the Bribery Act and formerly a member of the of the UK Government's Export Guarantees Advisory Committee. He has a degree from Oxford University, where he recently held a 3-year Visiting Fellowship, and a PhD from the European University Institute.

Maureen is Vice President within the Global Compliance Organization at MSD. She is responsible for leading the Office of Ethics, including: oversight of global compliance investigations program, anti-bribery and corruption, third party, policies, compliance training and communications. During her 21 years of work experience at MSD, Maureen held a number of positions within MSD's Office of General Counsel, including Managing Counsel in legal supporting the U.S. Human Health, Vaccines and Research divisions.

Ashley Watson is Merck's Senior Vice President, Chief Ethics and Compliance Officer. She leads a team of attorneys and compliance professionals responsible for Merck's policies, programs and investigations to ensure ethical decision making and compliance with laws and regulations globally.

Prior to joining Merck in March 2015, she served as Senior Vice President, Deputy General Counsel and Chief Ethics & Compliance Officer for Hewlett-Packard, as well as the company's Executive Director, HP Company Foundation. She was named Chief Compliance Officer of the Year by Women in Compliance in 2014.

Earlier in her career, Ashley served as senior litigation counsel for the BellSouth Corporation, handling a range of antitrust, securities, class actions and intellectual property litigation. Ashley received her J.D. from the University of Georgia and her B.A. in political science from the University of North Carolina.

Karen Eryou is currently Senior Director, Corporate Compliance, APAC for UCB. She has over 15 years of international work experience in the pharmaceutical industry including Clinical Operations, Quality Assurance, Auditing and Inspections, as well as Medical Affairs. She has focused on business practices, ethics and compliance topics for the past 5 years. Since 2011 Karen has been based in Shanghai where she was assigned to build the compliance function for UCB. Following the development and implementation of a comprehensive compliance program with the China team she now leads the compliance program for the Asia-Pacific region for UCB.

Katsumi KOJIMA is a Corporate officer, Country Compliance officer Japan of Sanofi Group, based in Tokyo, Japan. He is a member of the Code Compliance Committee, the Japanese Pharmaceutical Manufacturers Association (JPMA) and a member of the International Federation of Pharmaceutical Manufacturers and associations (IFPMA) Code Compliance Network.

He has been working for compliance field in the pharmaceutical and medical device industries over ten (10) years. He engaged in a speaker and a panellist on compliance topics in various conferences, such as "How Do I Know It's Working? Key Performance Indicators, Metrics and More" at Asia-Pacific Economic Cooperation (Nanjing, China) in 2014, "Venues & Locations of Third Party Conferences: What is Appropriate" at Advanced Medical Technology Association and Medical Technology Association of Australia Compliance Conference (Singapore) in 2014 and "Australia and Japan transparency updates" at the Global MedTech Compliance Conference (Barcelona, Spain) in 2014.

He earned LLB from Waseda University (Tokyo, Japan) and LLM from Hitotsubashi University (Tokyo, Japan). In addition, he received certification from INSEAD Compliance Implementation Leadership 1 (Fontainebleau, France) and Seton Hall Law School Aisa-Pacific Healthcare Compliance (Singapore). Since 2010, he has served as a Visiting Lecturer at Kyoto Prefectural University of Medicine (Kyoto, Japan).

As member of the Rx & D team and the Executive Director of Ethics and Compliance Practices, Chrisoula Nikidis is responsible for the Code of Ethical Practices and related issues. Her key responsibilities include maintaining and updating the Code, managing the Code education program, answering Code related questions, offering guidance on the application of the Code while providing expertise on industry practices. Included in her responsibilities is advice and support to the President of Rx & D in matters that pertain to the International Federation of Pharmaceutical Manufacturers Association (IFPMA) and the Code Compliance Network.

Prior to joining Rx & D, Chrisoula Nikidis was RFP Solutions' Senior Advisor for Bid Evaluations where she worked on assisting government officials with the proposal evaluation process and provided procurement related strategic advice.

Russell Williams is the President of Canada's Research-Based Pharmaceutical Companies (Rx&D), an association of over fifty innovative life sciences companies.

Reporting to the Executive and Board of Directors, Russell is responsible for overall corporate leadership, strategic direction, achieving priority objectives, public presence for the industry, issue management, compliance, as well as the management of human and financial resources.

His leadership is aimed at creating a better environment for improved life science research and healthcare sustainability.

Russell also chairs the international Code Compliance Network for the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), as well as being a member of the Council of the IFPMA.